StreetInsider.com News Articles

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Sandoz submits generic obesity drug applications to FDA

Mon, 29 Jun 2026 06:14:57 -0400

Investing.com -- Sandoz has submitted two generic versions of tirzepatide to the U.S. Food and Drug Administration for review. The drugs would compete with Eli Lilly's obesity and diabetes treatments Mounjaro and Zepbound if approved.

The Swiss generics drugmaker said the proposed medications would treat type-2 diabetes and weight management, matching the same conditions as Eli Lilly's branded products. Eli Lilly's tirzepatide patent expires in 2036 in the United States.

"Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement.

The FDA has not indicated how long

Sandoz submits generic obesity drug applications to FDA

Mon, 29 Jun 2026 06:14:57 -0400

"Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement.

The FDA has not indicated how long

Sandoz submits generic obesity drug applications to FDA

Mon, 29 Jun 2026 06:14:57 -0400

"Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement.

The FDA has not indicated how long

Why Kepler says this pharma stock is 'one-of-a-kind investment opportunity'

Wed, 14 Jan 2026 12:00:00 -0400

One European drugmaker is viewed by Kepler analysts as a “one-of-a-kind investment opportunity,” driven by unusually strong visibility on patent expiries and a pipeline that stretches well into the next decade.

Following a recent industry update in San Francisco, analyst Nicolas Pauillac said the company reinforced its long-term investment case by clearly mapping out how it plans to monetise a wave of loss-of-exclusivity events (LOEs) across generics and biosimilars.

The company Pauillac is referring to is Swiss generic drug manufacturer Sandoz (OTC: SDZNY).

After attending the event, the analyst highlighted Sandoz’s “very confident management team,” which provided additional detail on the scale

Why Kepler says this pharma stock is 'one-of-a-kind investment opportunity'

Wed, 14 Jan 2026 12:00:00 -0400

The company Pauillac is referring to is Swiss generic drug manufacturer Sandoz (OTC: SDZNY).

After attending the event, the analyst highlighted Sandoz’s “very confident management team,” which provided additional detail on the scale

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio.

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is